In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
AlHilli, Mariam M
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. [electronic resource] - Gynecologic oncology Nov 2016 - 379-388 p. digital
Publication Type: Journal Article
1095-6859
10.1016/j.ygyno.2016.08.328 doi
DNA-Binding Proteins--analysis
Female
Genes, BRCA2
Homologous Recombination
Humans
Indazoles--therapeutic use
Ovarian Neoplasms--drug therapy
Piperidines--therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use
Promoter Regions, Genetic
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. [electronic resource] - Gynecologic oncology Nov 2016 - 379-388 p. digital
Publication Type: Journal Article
1095-6859
10.1016/j.ygyno.2016.08.328 doi
DNA-Binding Proteins--analysis
Female
Genes, BRCA2
Homologous Recombination
Humans
Indazoles--therapeutic use
Ovarian Neoplasms--drug therapy
Piperidines--therapeutic use
Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use
Promoter Regions, Genetic